<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.thyroidresearchjournal.com/feeds/mostaccessed/journal?quantity=&amp;format=rss&amp;version=">
        <title>Thyroid Research - Most accessed articles</title>
        <link>http://www.thyroidresearchjournal.com</link>
        <description>The most accessed research articles published by Thyroid Research</description>
        <dc:date>2010-02-08T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.thyroidresearchjournal.com/content/3/1/1" />
                                <rdf:li rdf:resource="http://www.thyroidresearchjournal.com/content/2/1/11" />
                                <rdf:li rdf:resource="http://www.thyroidresearchjournal.com/content/2/1/4" />
                                <rdf:li rdf:resource="http://www.thyroidresearchjournal.com/content/2/1/2" />
                                <rdf:li rdf:resource="http://www.thyroidresearchjournal.com/content/2/1/12" />
                                <rdf:li rdf:resource="http://www.thyroidresearchjournal.com/content/1/1/4" />
                                <rdf:li rdf:resource="http://www.thyroidresearchjournal.com/content/2/1/10" />
                                <rdf:li rdf:resource="http://www.thyroidresearchjournal.com/content/1/1/7" />
                                <rdf:li rdf:resource="http://www.thyroidresearchjournal.com/content/2/1/9" />
                                <rdf:li rdf:resource="http://www.thyroidresearchjournal.com/content/2/1/5" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.thyroidresearchjournal.com/content/3/1/1">
        <title>Acute myocardial infarction as the first presentation of thyrotoxicosis in a 31-year old woman - case report</title>
        <description>A 31-year old woman, previously fit &amp; well was admitted with pressing retrosternal chest pain and palpitations of sudden onset. Her body weight was normal (BMI 20.5 kg/m2) and there was no significant family history of cardiac disease. She smoked, however, about 15 cigarettes a day and she had been taking combined oral contraceptive pill (Cilest&#174;) for about three years. On admission she appeared sweaty and in pain, blood pressure 130/70 mmHg, heart rate about 110/min, mild lid-lag sign. Heart sounds were normal and chest was clear. ECG revealed 2-3 mm ST segment elevations in II, III, aVF as well as V2 to V5. Troponin I was raised and she was qualified to an emergency coronary angiography. This revealed a massive spasm of left anterior descending (LAD) coronary artery that responded to intracoronary glyceryl trinitrite administration, however, with the presence of critical narrowing of the LAD apical segment with possible superimposed thrombus. Cardiac ultrasound revealed akinesis of 1/2 of apical area consistent with myocardial infarctionTreatment and progressShe was started on Aspirin, Simvastatin, and Diltiazem, but continued to have persistent tachycardia and tremor. Thyroid function tests were ordered and showed thyrotoxicosis [free T4-46.9 pmol/l (ref. range 9-25), free T3-11.9 pmol/l (2-5), TSH - 0.02 mIU/l (0.27-4.2)]. She was referred for an endocrine opinion and started on Thiamazole. Other investigations revealed elevated anti-TPO and anti-TSH receptor antibodies consistent with Graves&apos; disease. Thrombophilia screen was negative. She had remained euthyroid on a &quot;block &amp; replace&quot; regimen (Thiamazole plus L-Thyroxine) that was discontinued after 18 months. She denies any anginal symptoms, but continues to smoke against medical advice.
Conclusions:
Our case highlights the possibility of development of an acute myocardial infarction in a young subject with thyrotoxicosis. We speculate that patient&apos;s smoking habit combined with subtle thyrotoxicosis-induced prothrombotic state and/or coronary-artery spasm had lead to the above-mentioned acute coronary event.</description>
        <link>http://www.thyroidresearchjournal.com/content/3/1/1</link>
                <dc:creator>Krzysztof Lewandowski</dc:creator>
                <dc:creator>Tomasz Rechcinski</dc:creator>
                <dc:creator>Maria Krzeminska-Pakula</dc:creator>
                <dc:creator>Andrzej Lewinski</dc:creator>
                <dc:source>Thyroid Research 2010, 3:1</dc:source>
        <dc:date>2010-02-08T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6614-3-1</dc:identifier>
        <prism:publicationName>Thyroid Research</prism:publicationName>
        <prism:issn>1756-6614</prism:issn>
        <prism:volume>3</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2010-02-08T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.thyroidresearchjournal.com/content/2/1/11">
        <title>Congenital leptin deficiency and thyroid function</title>
        <description>Thyroid function is closely related to leptin&apos;s secretion by the adipose tissue. In states of leptin-deficiency, the circadian rhythm of TSH is altered, leading to central hypothyroidism in animal models. In humans, central hypothyroidism has also been described in rare cases of congenital leptin deficiency. However, the thyroid phenotype in these cases is heterogeneous, with the occurrence of central hypothyroidism in a minority of cases. Here we describe thyroid function in four leptin-deficient humans (2 males aged 5 and 27, and 2 females aged 35 and 40), before and during leptin replacement with recombinant human methionyl leptin (r-metHuLeptin). The child was evaluated for four years, and the adults, for eight years. In addition, the adults were submitted to a brief withdrawal of leptin during six weeks in the sixth year. Our results show that, regardless of leptin replacement, our leptin-deficient patients have normal thyroid function. In spite of having an important role in regulating the hypothalamic-pituitary-thyroidal axis, leptin is not required for normal thyroid function.Trial RegistrationClinicalTrials.gov Identifiers: NCT00659828 and NCT00657605</description>
        <link>http://www.thyroidresearchjournal.com/content/2/1/11</link>
                <dc:creator>Gilberto Paz-Filho</dc:creator>
                <dc:creator>Tuncay Delibasi</dc:creator>
                <dc:creator>Halil Erol</dc:creator>
                <dc:creator>Ma-Li Wong</dc:creator>
                <dc:creator>Julio Licinio</dc:creator>
                <dc:source>Thyroid Research 2009, 2:11</dc:source>
        <dc:date>2009-11-04T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6614-2-11</dc:identifier>
        <prism:publicationName>Thyroid Research</prism:publicationName>
        <prism:issn>1756-6614</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>11</prism:startingPage>
        <prism:publicationDate>2009-11-04T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.thyroidresearchjournal.com/content/2/1/4">
        <title>The mechanisms of atrial fibrillation in hyperthyroidism.</title>
        <description>Atrial fibrillation (AF) is a complex condition with several possible contributing factors. The rapid and irregular heartbeat produced by AF increases the risk of blood clot formation inside the heart. These clots may eventually become dislodged, causing embolism, stroke and other disorders. AF occurs in up to 15% of patients with hyperthyroidism compared to 4% of people in the general population and is more common in men and in patients with triiodothyronine (T3) toxicosis. The incidence of AF increases with advancing age. Also, subclinical hyperthyroidism is a risk factor associated with a 3-fold increase in development of AF. Thyrotoxicosis exerts marked influences on electrical impulse generation (chronotropic effect) and conduction (dromotropic effect). Several potential mechanisms could be invoked for the effect of thyroid hormones on AF risk, including elevation of left atrial pressure secondary to increased left ventricular mass and impaired ventricular relaxation, ischemia resulting from increased resting heart rate, and increased atrial eopic activity. Reentry has been postulated as one of the main mechanisms leading to AF. AF is more likely if effective refractory periods are short and conduction is slow. Hyperthyroidism is associated with shortening of action potential duration which may also contribute to AF.</description>
        <link>http://www.thyroidresearchjournal.com/content/2/1/4</link>
                <dc:creator>Agata Bielecka-Dabrowa</dc:creator>
                <dc:creator>Dimitri Mikhailidis</dc:creator>
                <dc:creator>Jacek Rysz</dc:creator>
                <dc:creator>Maciej Banach</dc:creator>
                <dc:source>Thyroid Research 2009, 2:4</dc:source>
        <dc:date>2009-04-02T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6614-2-4</dc:identifier>
        <prism:publicationName>Thyroid Research</prism:publicationName>
        <prism:issn>1756-6614</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2009-04-02T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.thyroidresearchjournal.com/content/2/1/2">
        <title>Association between primary hypothyroidism and metabolic syndrome and the role of C reactive protein: a cross - sectional study from South India</title>
        <description>Background:
Hypothyroidism (sub-clinical and overt) and metabolic syndrome are recognized risk factors for atherosclerotic cardiovascular disease. This study is an effort to identify the proposed association between these two disease entities and the risk factors involved in this association.
Methods:
A cross &#8211; sectional study from a tertiary care teaching hospital in Chennai city, South India. 420 patients with metabolic syndrome (NCEP &#8211; ATP III criteria) were included in the study group. 406 appropriately age and sex matched controls having no features of metabolic syndrome (0 out of the 5 criteria) were compared with the study group. The study extended over a 5 year period. TSH, FT4 were measured for both the groups using electrochemiluminescence immuno assay. HsCRP was measured for all the patients in the study group. The baseline characteristics between the groups were compared with Student&apos;s&apos;t&apos; test. Chi-square test was used to analyze the association between metabolic syndrome and hypothyroidism (overt and sub-clinical). Logistic regression analysis was applied to identify the association between hypothyroidism and the patient characteristics in the study group.
Results:
Of the 420 patients in the study group, 240 were females (57.1%), 180 were males (42.9%) with mean age 51 &#177; 9.4 years. Of the 406 patients in the control group, 216 were females (53.2%), 190 males (46.8%) with mean age 49 &#177; 11.2 years. In the study group, 92 had sub-clinical hypothyroidism (SCH) (21.9%), 31 were overtly hypothyroid (7.4%) and 297 were euthyroid (70.7%). In the control group 27 patients had sub-clinical hypothyroidism (6.6%), 9 patients had overt hypothyroidism (2.2%) and 370 patients were euthyroid (91.2%). On comparison SCH (P &lt; 0.001) and overt hypothyroidism (P &lt; 0.001) were significantly associated with the study group as compared to the control group. Logistic regression analysis recognized the association between female gender (P = 0.021) and HsCRP (P = 0.014) with sub-clinical hypothyroidism and female gender (P = 0.01) with overt hypothyroidism in the study group.
Conclusion:
Hypothyroidism is associated with metabolic syndrome and females are more at risk. Metabolic syndrome patients with a raised HsCRP are at significant risk of having sub-clinical hypothyroidism.</description>
        <link>http://www.thyroidresearchjournal.com/content/2/1/2</link>
                <dc:creator>Ghanshyam Palamaner Subash Shantha</dc:creator>
                <dc:creator>Anita Kumar</dc:creator>
                <dc:creator>Vijay Jeyachandran</dc:creator>
                <dc:creator>Deepan Rajamanickam</dc:creator>
                <dc:creator>Rajkumar K</dc:creator>
                <dc:creator>Shihas Salim</dc:creator>
                <dc:creator>Kuyilan Karai Subramanian</dc:creator>
                <dc:creator>Senthilkumar Natesan</dc:creator>
                <dc:source>Thyroid Research 2009, 2:2</dc:source>
        <dc:date>2009-03-09T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6614-2-2</dc:identifier>
        <prism:publicationName>Thyroid Research</prism:publicationName>
        <prism:issn>1756-6614</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>2</prism:startingPage>
        <prism:publicationDate>2009-03-09T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.thyroidresearchjournal.com/content/2/1/12">
        <title>The influence of hepatitis C infection and interferon-alpha therapy on thyrotropin blocking and stimulating autoantibodies in Graves&apos; ophthalmopathy: a case report</title>
        <description>Background:
Hepatitis C virus is a highly immunogenic pathogen often inducing autoimmune activation changes and this can often be further exacerbated by Interferon therapy. As HCV is lymphocytotropic, it can modulate T cell and B cell antibody responses, affecting many endocrine organs, most commonly the thyroid.Case presentationWe hereby describe a case of fluctuating and wavering thyrotropin autoantibodies of both stimulating and blocking nature in the setting of Graves&apos;s ophthalmopathy, hepatitis C infection and interferon-&#945;, causing hypo- and subsequently hyper-thyroidism. The autoantibody profile was clearly modified during interferon therapy and settled into a new equilibrium at the completion of treatment.
Conclusion:
The case highlights the possible existence of a dual thyroid autoantibody population associated with hepatitis C, and its modulation by interferon therapy, which further compounds the difficulties in the assessment thyroid disease in this setting.</description>
        <link>http://www.thyroidresearchjournal.com/content/2/1/12</link>
                <dc:creator>Huy Tran</dc:creator>
                <dc:creator>Glenn Reeves</dc:creator>
                <dc:source>Thyroid Research 2009, 2:12</dc:source>
        <dc:date>2009-12-02T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6614-2-12</dc:identifier>
        <prism:publicationName>Thyroid Research</prism:publicationName>
        <prism:issn>1756-6614</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>12</prism:startingPage>
        <prism:publicationDate>2009-12-02T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.thyroidresearchjournal.com/content/1/1/4">
        <title>To bind or not to bind - how to down-regulate target genes by liganded thyroid hormone receptor?</title>
        <description>The terrain is well explored regarding genes whose gene expression is up-regulated upon binding of thyroid hormone (TH) to its nuclear receptor. This regulation mechanism has been intensively studied and is well understood. In contrast, a lot of white spots remain on the map when it comes to target genes whose expression is down-regulated upon binding of TH to the thyroid hormone receptor (TR). Since no consistent mechanism has been proposed to explain ligand-dependent down-regulation of target gene transcription several working hypotheses favour different molecular mechanisms. Some working theories suggest a direct binding of TR to regulatory elements of target genes. Others favour models that are independent of a direct DNA binding event. However recent data suggested that a direct binding of TR to DNA is dispensable for TH-dependent negative gene transcription.</description>
        <link>http://www.thyroidresearchjournal.com/content/1/1/4</link>
                <dc:creator>Joachim Weitzel</dc:creator>
                <dc:source>Thyroid Research 2008, 1:4</dc:source>
        <dc:date>2008-10-11T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6614-1-4</dc:identifier>
        <prism:publicationName>Thyroid Research</prism:publicationName>
        <prism:issn>1756-6614</prism:issn>
        <prism:volume>1</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2008-10-11T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.thyroidresearchjournal.com/content/2/1/10">
        <title>Association of polymorphism in genes encoding kappa B inhibitors (IkappaB) with susceptibility to and phenotype of Graves&apos; disease: a case-control study</title>
        <description>Background:
Genes related to the nuclear factor-&#954;B (NF-&#954;B), a key transcription factor involved in regulation of immune responses, are interesting candidates for association studies in autoimmune disorders. The aim of this study was to investigate an association of polymorphisms in two genes encoding NF-&#954;B inhibitors: IKBL (encoding inhibitor of &#954;B-like) and NFKBIA (encoding &#954;B inhibitor &#945;), withsusceptibility to and phenotype of Graves&apos; disease (GD).
Methods:
A population-based, case-control association study comprising 481 patients with GD and 455 healthy controls was performed. We analyzed 3 single nucleotide polymorphisms (SNPs) in IKBL [promoter region -62T/A substitution (rs2071592), intron 1 C/T substitution (rs2071591) and exon 4 T/C substitution (rs3130062)] and 3 SNPs in NFKBIA [G/A substitution in 3&apos; untranslated region (rs696) and two promoter region polymorphisms -297C/T (rs2233409) and -826C/T (rs2233406)] by the PCR-restriction fragment length polymorphism (RFLP) method.
Results:
The two SNPs in IKBL (rs2071592 and rs2071591) were in a strong linkage disequilibrium (D&apos; = 0.835) and the AT haplotype was associated with susceptibility to GD (p &lt; 10-4, OR = 1.61 [95%CI:1.21-2.14]). Moreover subgroup analysis revealed a gen-gen interaction between the investigated IKBL haplotype and HLA-DRB1*03 allele (p &lt; 10-4). The investigated NFKBIA SNPs were not associated with susceptibility to GD. However, when correlated with phenotype, the -297T (rs2233409) and -826T (rs2233406) alleles were associated with the development of clinically evident ophthalmophaty (p = 0.004, pc = 0.07, OR = 1.65 [95%CI: 1.18-2.38] and p = 0.002, pc = 0.036, OR = 1.67 [95%CI: 1.20-2.36], respectively).
Conclusion:
Our results suggest that SNPs in genes encoding NF-&#954;B inhibitors may contribute to the development and clinical phenotype of GD.</description>
        <link>http://www.thyroidresearchjournal.com/content/2/1/10</link>
                <dc:creator>Alina Kurylowicz</dc:creator>
                <dc:creator>Piotr Miskiewicz</dc:creator>
                <dc:creator>Ewa Bar-Andziak</dc:creator>
                <dc:creator>Janusz Nauman</dc:creator>
                <dc:creator>Tomasz Bednarczuk</dc:creator>
                <dc:source>Thyroid Research 2009, 2:10</dc:source>
        <dc:date>2009-11-03T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6614-2-10</dc:identifier>
        <prism:publicationName>Thyroid Research</prism:publicationName>
        <prism:issn>1756-6614</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>10</prism:startingPage>
        <prism:publicationDate>2009-11-03T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.thyroidresearchjournal.com/content/1/1/7">
        <title>New onset Graves&apos; disease as a cause of an adrenal crisis in an individual with panhypopituitarism: brief report </title>
        <description>46 year old patient was admitted as an emergency with vomiting, hypotension and serum cortisol of 0,940 &#956;g/dl (26 nmol/l) indicative of adrenal failure. Despite previous history of panhypopituitarism he was found to be hyperthyroid [free T4 6.32 ng/dl (ref. range: 0.93&#8211;1.7), free T3 22.21 pg/ml (ref. range: 1.8&#8211;4.6)]. He was fit and well till the age of 45. Eight months prior to this hospitalisation he presented with diabetes insipidus and was found to have a large cystic tumour in the area of the pituitary gland. Surgery was only partially successful and histologically the tumour was diagnosed as craniopharyngioma. Endocrine assessment revealed deficiency in ACTH-cortisol, growth hormone, and gonadotropin, as well as low-normal free T4. On the day of his emergency admission he looked ill and dehydrated, though was fully conscious and cooperative. Heart rate was 120 beats/min (sinus rhythm), blood pressure 85/40 mm Hg. There were no obvious features of infection, but there was marked tremor and thyroid bruit. He received treatment with intravenous fluids and hydrocortisone. L-thyroxine was stopped. Administration of large dose of methimazole (60 mg/day) resulted in gradual decrease in free T4 and free T3 (to 1.76 ng/ml, and 5.92 pg/ml, respectively) over a 15-day period. The patient was found to have increased titre of antithyroperoxidase (anti-TPO) and anti-TSH receptor (anti-TSHR) antibodies [2300 IU/l (ref. range &lt;40) and 3.6 IU/l (ref. range &lt;1.0), respectively]. He was referred for radioactive iodine treatment. Iodine uptake scan performed prior to radioiodine administration confirmed uniformly increased iodine uptake consistent with Graves&apos; disease.
Conclusion:
Our case illustrates coexistence of hypopituitarism and clinically significant autoimmune thyroid disease. The presence of hypopituitarism does not preclude the development of autoimmune thyrotoxicosis.</description>
        <link>http://www.thyroidresearchjournal.com/content/1/1/7</link>
                <dc:creator>Krzysztof Lewandowski</dc:creator>
                <dc:creator>Magdalena Marcinkowska</dc:creator>
                <dc:creator>Elzbieta Skowronska-Jozwiak</dc:creator>
                <dc:creator>Jacek Makarewicz</dc:creator>
                <dc:creator>Andrzej Lewinski</dc:creator>
                <dc:source>Thyroid Research 2008, 1:7</dc:source>
        <dc:date>2008-11-19T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6614-1-7</dc:identifier>
        <prism:publicationName>Thyroid Research</prism:publicationName>
        <prism:issn>1756-6614</prism:issn>
        <prism:volume>1</prism:volume>
        <prism:startingPage>7</prism:startingPage>
        <prism:publicationDate>2008-11-19T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.thyroidresearchjournal.com/content/2/1/9">
        <title>A minute focus of extranodal marginal zone B-cell lymphoma arising in Hashimoto thyroiditis diagnosed with PCR after laser capture microdissection: a case report

</title>
        <description>Background:
Primary thyroid gland lymphomas are uncommon tumours that occur in the setting of lymphocytic thyroiditis or Hashimoto&apos;s disease in almost all cases. In this condition a distinction between an inflammatory lymphoid infiltrate and a low grade lymphoma may be extremely difficult and precise criteria are necessary for a correct diagnosis.Patient and methodsWe report a case of a minute focus of primary extranodal marginal zone B-cell lymphoma (EMZBCL), incidentally discovered in a 63-year-old man with Hashimoto thyroiditis (HT) and diagnosed by means of polymerase chain reaction (PCR) after laser capture microdissection.The histological examination of surgical specimen confirmed the diagnosis of HT and showed a minute focus of dense lymphoid infiltrate (less than 4 mm in diameter), composed by centrocyte-like cells forming MALT balls. Immunoistochemistry was not useful. A microscopic focus of EMZBCL was suspected on the basis of morphological features. PCR assays revealed the rearrangement of the heavy chain of immunoglobulins only in the microdissected suspicious area, confirming the diagnosis of EMZBCL.
Conclusion:
Our finding suggests that in cases of autoimmune thyroiditis a careful examination of the thyroid specimen is warranted, in order to disclose areas or small foci of lymphomatous transformation. Furthermore, in difficult cases with doubtful immunohistological findings, ancillary techniques, such as molecular studies, are necessary for a conclusive diagnosis.</description>
        <link>http://www.thyroidresearchjournal.com/content/2/1/9</link>
                <dc:creator>Antonio D'Antonio</dc:creator>
                <dc:creator>Alessia Caleo</dc:creator>
                <dc:creator>Stefano Licci</dc:creator>
                <dc:creator>Maria Addesso</dc:creator>
                <dc:creator>Maurizio De Palma</dc:creator>
                <dc:creator>Amedeo Boscaino</dc:creator>
                <dc:creator>Oscar Nappi</dc:creator>
                <dc:source>Thyroid Research 2009, 2:9</dc:source>
        <dc:date>2009-09-07T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6614-2-9</dc:identifier>
        <prism:publicationName>Thyroid Research</prism:publicationName>
        <prism:issn>1756-6614</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>9</prism:startingPage>
        <prism:publicationDate>2009-09-07T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.thyroidresearchjournal.com/content/2/1/5">
        <title>Endogenous avidin biotin activity (EABA) in thyroid pathology: immunohistochemical study</title>
        <description>Background:
Immunohistochemical methods based on the high affinity of avidin and biotin (e.g. ABC, LSAB) are characterized by high sensitivity and are widely used for detection of immunologic reaction. However, a non-specific reaction, observed in frozen tissues and in paraffin-embedded material, increasing after heat induced epitope retrieval (HIER), and caused either by endogenous biotin or any another chemical compound with high affinity for avidin, may lead to diagnostic mistakes. The aim of our investigation is to study presence of endogenous avidin biotin activity (EABA) in thyrocytes originating from various thyroid pathological lesions (neoplastic and non-neoplastic).Materials and methodsThe immunohistochemical study was performed on paraffin-embedded specimens of surgically resected thyroid tissue from 97 patients with thyroid diseases: 65 patients with papillary carcinoma (PTC), 11 patients with nodular goiter in whom features of benign papillary hyperplasia were found, 9 with lymphocytic thyroiditis (LT), 8 with follicular adenoma, and 4 patients with follicular carcinoma. In PTC immunohistochemical study was performed both in primary tumors and in lymph node metastases. After HIER, incubation with streptavidin from LSAB+ (DakoCytomation) kit was done.
Results:
Strong cytoplasmic EABA was observed in 56 of 65 (87.5%) PTC and in oxyphilic cells in 8 of 9 cases of LT. Significant correlation between EABA in primary PTC tumor and EABA in lymph node metastases was stated. Normal surrounding thyroid tissues showed absence or weak EABA. Aberrant intranuclear localization of biotin was noted in morules of cribriform-morular variant of PTC. No statistically significant correlation between patient&apos;s age, sex, metastases presence and EABA was observed.
Conclusion:
Among thyroid lesions, false positive reactions are highly probable in papillary thyroid carcinoma and in lymphocytic thyroiditis if immunohistochemical detection is used on systems containing (strept)avidin. The most probable reason is the high endogenous biotin content.</description>
        <link>http://www.thyroidresearchjournal.com/content/2/1/5</link>
                <dc:creator>Nikiel Barbara</dc:creator>
                <dc:creator>Mykola Chekan</dc:creator>
                <dc:creator>Michal Jarzab</dc:creator>
                <dc:creator>Dariusz Lange</dc:creator>
                <dc:source>Thyroid Research 2009, 2:5</dc:source>
        <dc:date>2009-04-08T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-6614-2-5</dc:identifier>
        <prism:publicationName>Thyroid Research</prism:publicationName>
        <prism:issn>1756-6614</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>5</prism:startingPage>
        <prism:publicationDate>2009-04-08T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
